Welcome
By clicking "Continue to the HCP site," you are certifying that you are a licensed US healthcare professional (HCP) and a US resident.
If you are a patient who wants to learn more about VASCEPA, click vascepa.com
E-prescribe VASCEPA to BlinkRx U.S.
If your patients obtain their VASCEPA prescription via a mail order program, click the link below to download an editable PDF form to determine reimbursement of a patient’s copayment or out-of-pocket expenses.
• VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components
• VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter
• It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur
• VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease
• VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia
The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
• VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin
• Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%) and atrial fibrillation (5% vs 4%)
• Common adverse reactions in the hypertriglyceridemia trials (incidence ≥1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%)
• Adverse Events, Product Complaints, or Special Situations may be reported by contacting AmarinConnect at 1-855-VASCEPA, emailing [email protected], or calling the FDA at 1-800-FDA-1088
• Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding
Please see full Prescribing Information for more information on VASCEPA.
Visual representations are for illustrative purposes only. The capsule shown is not an identical representation of the product.
*Data based on analysis of DRG formulary data and Symphony claims data of patients’ final out-of-pocket cost, with eligible, commercially insured patients using the VASCEPA Savings Card. Data on file.
†Universal Pharmacy Card (UPC) may be applied for any eligible patient by entering all 4 codes into the notes section of an e-prescription.
‡This offer is valid only for eligible commercially insured patients with a valid VASCEPA® (icosapent ethyl) prescription. Patients whose prescriptions are covered or reimbursable in whole or in part by Medicare (including Medicare Part D and Medicare Advantage), Medicaid, TRICARE, DOD or any other federal or state program are not eligible for this offer. Offer may be used by eligible patients for a maximum savings of $2400 annually, for up to $160 per 1-month fill and $480 per 3-month fill. Offer only available in the United States. Void in MA and where otherwise prohibited by law or restricted by a third party. It may not be redeemed for cash. It is not transferable and may not be combined with any other savings offer or used for any other product. This is not health insurance. BlinkRx and AmarinPharma, Inc. reserve the right to rescind, revoke or amend this offer at any time with or without notice. It is a violation of federal law to buy, sell or counterfeit this offer. Cash-paying patients not using insurance who acknowledge and agree they cannot submit any portion of such payment for reimbursement to any insurance or other third-party are alternatively eligible for a 30-day supply for $99.
§Available to eligible patients with commercial insurance coverage only. Patients must have a valid prescription for VASCEPA® (icosapent ethyl) and a prior authorization request from their insurer on file. Subject to terms and conditions, program provides for a 30-day fill of VASCEPA at no charge to patients while their prior authorization request is being processed and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare (including Medicare Part D and Medicare Advantage), Medicaid, TRICARE, DOD or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed under this program. Limitations may apply.
Reference: 1. Kaiser Family Foundation. Employer health benefits: 2021 annual survey. https://files.kff.org/attachment/Report-Employer-Health-Benefits-2021-Annual-Survey.pdf. Accessed February 16, 2022.